Myers Michael, CEO, reported an open-market or private purchase at Quoin Pharmaceuticals, Ltd. involving 20490.000000 shares for an estimated $99991.20. Reported holdings after the transaction were 37713.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical tr…
0 other filings
0 recent txs